Abstract: Objective To observe the clinical efficacy of rosuvastatin combined with ezetimibe in the treatment of patients with acute myocardial infarction(AMI)by percutaneous coronary intervention(PCI). Methods Totally 120 AMI patients with PCI were selected and randomly divided into two groups, with 60 cases in each group. Observation group was treated with rosuvastatin and ezetimibe, while control group was treated with rosuvastatin. After 12 months of follow-up, the biochemical indexes ［serum total cholesterol(TC), triglyceride(TG), low density lipoprotein cholesterol(LDL-C), high density lipoprotein cholesterol(HDL-C)］, inflammatory indexes ［high sensitivity C-reactive protein(hs-CRP), interleukin-6(IL-6), tumor necrosis factor-α(TNF-α)］, cardiac function parameters ［N-terminal pro-B-type natriuretic peptide(NT-proBNP), left ventricular end diastolic diameter(LVEDD), left ventricular ejection fraction(LVEF)］, incidence of major adverse cardiovascular events and coronary artery disease were compared between two groups. Results The levels of TC, TG and LDL-C in the observation group were significantly lower than those in the control group at 3, 6, 9 and 12 months after operation, and the HDL-C level was significantly higher than that in the control group(P<0.05). The levels of hs-CRP, IL-6, TNF-α, NT-proBNP and LVEDD in the observation group were significantly lower than those in the control group at 3, 6, 9 and 12 months after operation, and the LVEF was significantly higher than that in the control group(P<0.05). The incidence rates - of acute myocardial infarction, angina pectoris, in-stent restenosis and new coronary artery disease in the observation group were significantly lower than those in the control group(P<0.05). Conclusion Rosuvastatin combined with ezetimibe can effectively reduce the levels of blood lipid and inflammatory factors in AMI patients, improve cardiac function, and reduce the incidence rates of coronary artery disease and adverse events.